Associate Professor
Infectious Disease
Dr. Anna P. Durbin, MD
|
|
Give Review
Anna Durbin works in the field of Infectious Disease. She graduated from Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care Doctor Anna P. Durbin, MD is a published doctor. She has 69 publications published. The most current publication "Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human par..."
Publications
- Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
- Dengue Human Infection Models to Advance Dengue Vaccine Development.
- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healt...
- The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
- New chapter unfolding in the fight against dengue with an unwritten ending.
- The mechanism and significance of cell type-dependent neutralization of flaviviruses.
- Viral kinetics of primary dengue virus infection in non-human primates: A systematic review and individual pooled analysis.
- The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
- Response to Ruiz-Alejo et al.
- The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.
- Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.
- Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.
- Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.
- A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clini...
- Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria.
- Decay and Persistence of Maternal Dengue Antibodies among Infants in Bangkok.
- A Single Dose of the DENV-1 Candidate Vaccine rDEN1??30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial.
- Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vac...
- A dynamic landscape for antibody binding modulates antibody-mediated neutralization of west nile virus.
- Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.
- Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
- HIV-1 evolution following transmission to an HLA-B*5801-positive patient.
- Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
- The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
- Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
- Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to ...
- Antigenic relationships between sylvatic and endemic dengue viruses.
- Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.
- Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
- rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
- The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
- Development of a live attenuated dengue virus vaccine using reverse genetics.
- Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
- rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
- Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
- Sensitivity and specificity of an improved rapid latex agglutination test for identification of methicillin-sensitive and -resistant Staphylococcus aureus isolates.
- Relationship between indole production and differentiation of Klebsiella species: indole-positive and -negative isolates of Klebsiella determined to be clonal.
- A pseudoepidemic due to laboratory contamination deciphered by molecular analysis.
- Variation and persistence of methicillin-resistant Staphylococcus aureus strains among individual patients over extended periods of time.
- A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosq...
- Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
- Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PI...
- Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phe...
- African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
- A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
- A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the ...
- Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
- Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a...
- A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces compl...
- Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human par...
- The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
- Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by thos...
- Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive ...
- Recovery of infectious human parainfluenza virus type 3 from cDNA.
- Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.
- Next-generation dengue vaccines: novel strategies currently under development.
- Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
- Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.
- Targeted mutagenesis as a rational approach to dengue virus vaccine development.
- Dengue vaccine candidates in development.
- Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system.
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
- Prospects for a dengue virus vaccine.
- Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.
- Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali.
- Report of an NIAID workshop on dengue animal models.
- Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
- First-generation immigrants and hospital admission rates for psychosis and affective disorders: an ecological study in Ontario.
Schools
Wayne State University
Detroit Rec Hsp University Health C
Wayne St University Detroit M C
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Wayne State University School of Medicine
Hospital
-
Johns Hopkins Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Myron M. Levine, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jay S. Goodman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shmuel Shoham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramona M. Sobhani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ikwo K. Oboho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan E. Reller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry W. Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Simon Dufresne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Wolde-Rufael, MD
This Doctor is OpenDoctor Recommended.
|